Molecular insights into endocrine resistance

European Journal of Cancer, Supplement

Volumn 3, Issue 3, 2005, Pages 225-236

  Johnston, Stephen R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANASTROZOLE; AZD 0530; AZD 3409; AZD 5438; AZD 6244; BORTEZOMIB; CANATERNIB; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; LONAFARNIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PELITINIB; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZF 1839;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENDOCRINE SYSTEM; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION;

EID: 27344458701     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(05)80279-4     Document Type: Article

References (82)

1. Johnston SR, and Dowsett M Aromatase inhibitors for breast cancer: lessons from the laboratory Nat Rev Cancer 3 11 2003 821 831
2. Kumar V, Green S, and Stack G Functional domains of the human estrogen receptor Cell 51 1987 941 951
3. Tzukerman MT, Esty A, and Santisomere D Human estrogen receptor transcriptional capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions Mol Endocrinol 8 1994 21 30
4. Kuiper GG, Enmark E, and Pelto-Huikko M Cloning of a novel estrogen receptor expressed in rat prostate and ovary Proc Natl Acad Sci USA 93 1996 5925 5930
5. Cowley SM, and Parker MG A comparison of transcriptional activation by ER alpha and ER beta J Steroid Biochem Mol Biol 69 1-6 1999 165 175
6. Montano M, Muller V, and Trobaugh A The carboxy-terminal F domain of the human estrogen receptor; role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists Mol Endocrinol 9 1995 814 825
7. Spiers V, Parkes AT, and Kerin MJ Coexpression of estrogen receptor alpha and beta; poor prognostic factors in human breast cancer Cancer Res 59 1999 525 528
8. Webb P, Lopez GN, Uht RM, and Kushner PJ Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens Mol Endocrinol 9 1995 443 456
9. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, and Kushner PJ Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites Science 277 1997 1508 1510
10. Schiff R, Reddy P, and Coronado E Development of tamoxifen-stimulated growth in-vivo is associated with changes in AP-1 activity Breast Cancer Res Treat 46 1997 A347
11. Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, and Dowsett M Increased activator protein-1 DNA binding and c-jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance Clin Cancer Res 5 1999 251 256
12. Smith CL, Nawaz Z, and O' Malley BW Coactivator and co-repressor regulation of the agonist/antagonist activity of the mixed antiestrogen 4-hydroxytamoxifen Mol Endocrinol 11 1997 657 666
13. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen T-M, and Schiff R Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes Proc Natl Acad Sci USA 95(6) 1998 2920 2925
14. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, and Grohe C Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway J Biol Chem 275 24 2000 18447 18453
15. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, and Liao JK Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase Nature 407 6803 2000 538 541
16. Levin ER Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor Mol Endocrinol 17 3 2003 309 317
17. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, and Weiss H Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 12 2004 926 935
18. Osborne CK, and Schiff R Estrogen-receptor biology: continuing progress and therapeutic implications J Clin Oncol 23 8 2005 1616 1622
19. discussion 92-100 Mass R The role of HER-2 expression in predicting response to therapy in breast cancer Semin Oncol 27 6 Suppl 11 2000 46 52
20. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, and Janicke F Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 2001 3808 3816
21. abstr 1 Smith I, and Dowsett M Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial Breast Cancer Res Treat 82 2003 S6
22. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, and Fuqua SA Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 5 2003 353 361
23. Bardou VJ, Arpino G, Elledge RM, Osborne CK, and Clark GM Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 10 2003 1973 1979
24. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, and Mills GB Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Mol Endocrinol 17 4 2003 575 588
25. Petz LN, Ziegler YS, Schultz JR, and Nardulli AM Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site Mol Endocrinol 18 3 2004 521 532
26. abstr 33 Massarweh S, Osborne CK, Wakeling AE, and Schiff R Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation Breast Cancer Res Treat 82 2004 S18
27. Osborne CK, Shou J, Massarweh S, and Schiff R Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer Clin Cancer Res 11 2 Pt 2 2005 865s 870s
28. (abstr 511) Thurlimann BJ, Keshaviah A, Mouridsen H, Mauriac L, Forbes JF, and Paridaens R BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Proc Am Soc Clin Oncol 23 2005 6s
29. Paik S, Shak S, Tang G, Kim C, Baker J, and Cronin M A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer N Engl J Med 351 27 2004 2817 2826
30. Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, and Rose C Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women Cancer Treat Rep 63 1979 171 175
31. Smith IE, and Dowsett M Aromatase inhibitors in breast cancer N Engl J Med 348 24 2003 2431 2442
32. Johnston SRD, Saccani-Jotti G, Smith IE, Salter J, Newby J, and Coppen M Changes in estrogen receptor, progesterone receptor and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 55 1995 3331 3338
33. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, and Allred DC Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase J Clin Oncol 23 11 2005 2469 2476
34. Parl FF Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer Pharmacogenomics J 3 5 2003 251 253
35. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, and Davidson NE Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells Cancer Res 61 19 2001 7025 7029
36. Wolf DM, and Jordan VC The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain Breast Cancer Res Treat 31 1 1994 129 138
37. Karnik PS, Kulkarni S, Liu XP, Budd GT, and Bukowski RM Estrogen receptor mutations in tamoxifen-resistant breast cancer Cancer Res 54 2 1994 349 353
38. Andersen TI, Wooster R, Laake K, Collins N, Warren W, and Skrede M Screening for ESR mutations in breast and ovarian cancer patients Hum Mutat 9 6 1997 531 536
39. Dowsett M, Daffada A, Chan CM, and Johnston SR Oestrogen receptor mutants and variants in breast cancer Eur J Cancer 33 8 1997 1177 1183
40. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, and Friedrichs WE A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions Cancer Res 60 15 2000 4026 4029
41. Johnston SRD Acquired tamoxifen resistance in human breast cancer, potential mechanisms and clinical implications Anticancer Drugs 8 1997 911 930
42. DeFriend DJ, Anderson E, Bell J, Wilks DP, West CM, and Mansel RE Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro Br J Cancer 70 2 1994 204 211
43. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, and Kleeberg UR Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 16 2002 3396 3403
44. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, and Come S Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 16 2002 3386 3395
45. McClelland RA, Barrow D, Madden T-A, Dutkowski CM, Pamment J, and Knowlden JM Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex) Endocrinology 142 7 2001 2776 2788
46. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, and Harper ME Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 3 2003 1032 1044
47. Stoica GE, Franke TF, Wellstein A, Czubayko F, List HJ, and Reiter R Estradiol rapidly activates Akt via the ErbB2 signaling pathway Mol Endocrinol 17 5 2003 818 830
48. Font de Mora J, and Brown M AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor Mol Cell Biol 20 14 2000 5041 5047
49. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, and Coronado E Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu Breast Cancer Res Treat 24 2 1993 85 95
50. Kao YC, Cam LL, Laughton CA, Zhou D, and Chen S Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study Cancer Res 56 1996 3451 3460
51. Sourdaine P, Parker MG, Telford J, and Miller WR Analysis of the aromatase cytochrome P450 gene in human breast cancers J Mol Endocrinol 13 1994 331 337
52. Dowsett M, Stein RC, and Coombes RC Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients J Steroid Biochem Mol Biol 43 1992 155 159
53. Masamura S, Santner SJ, Heitjan DF, and Santen RJ Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells J Clin Endocrinol Metab 80 1995 2918 2925
54. Santen RJ Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients J Steroid Biochem Mol Biol 79 2001 115 125
55. Chan CMW, Martin L.-A, Johnston SRD, Ali S, and Dowsett M Molecular changes associated with acquisition of estrogen hypersensitivity in MCF-7 breast cancer cells on long-term estrogen deprivation J Steroid Biochem Mol Biol 81 2002 333 341
56. Martin L-A, Farmer I, Johnston SRD, Ali S, Marshall C, and Dowsett M Enhanced ER alpha, ERB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation J Biol Chem 278 2003 30458 30468
57. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, and Santen RJ The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane Proc Natl Acad Sci USA 101 2004 2076 2081
58. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, and Yue W Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells Mol Cell Endocrinol 193 2002 29 42
59. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, and Santen RJ Linkage of rapid estrogen action to MAPK activation by ER alpha-Shc association and Shc pathway activation Mol Endocrinol 16 2002 116 127
60. Nicholson RI, Staka C, Boyns F, Hutcheson IR, and Gee J Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer; new opportunities for therapy Endocrine Relat Cancer 11 2004 623 641
61. Yue W, Wang JP, Conaway MR, Li Y, and Santen RJ Adaptive hypersensitivity following long-term estrogen deprivation; involvement of multiple signal pathways J Steroid Biochem Mol Biol 86 2003 265 274
62. Jeng M-H, Yue W, Eischeid A, Wang J-P, and Santen RJ Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells Breast Cancer Res Treat 62 2000 167 175
63. Stephen RL, Shaw LE, Larsen C, Corcoran D, and Darbre PD Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF-7 human breast cancer cells J Biol Chem 276 2001 40080 40086
64. Nicholson RI, McClelland RA, Robertson JRF, and Gee JMW Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer Endocrine Relat Cancer 6 1999 373 387
65. Jeng MH, Yue W, Eischeid A, Wang JP, and Santen RJ Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells Breast Cancer Res Treat 62 2000 167 175
66. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, and Jordan N Nonendocrine Pathways and Endocrine Resistance Observations with Antiestrogens and Signal Transduction Inhibitors in Combination Clin Cancer Res 10 2004 346S 354S
67. Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, and Forbes JT Inhibition of HER2/neu (erbB-2) and Mitogen-activated Protein Kinases Enhances Tamoxifen Action against HER2-overexpressing, Tamoxifen-resistant Breast Cancer Cells Cancer Res 60 2000 5887 5894
68. Witters L, Engle L, and Lipton A Restoration of estrogen responsiveness by blocking the HER-2/neu pathway Oncol Rep 9 2002 1163 1166
69. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, and Gibbons JJ mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocrine Relat Cancer 8 2001 249 258
70. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, and Knowlden JM The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 2003 5105 5117
71. (A130) Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling AE, Osborne CK, and Schiff R Inhibition of epidermal growth factor / HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors Proc Am Soc Clin Oncol 21 2002 33a
72. Argiris A, Wang CX, Whalen SG, and DiGiovanna MP Synergistic interactions between tamoxifen and trastuzumab (Herceptin) Clin Cancer Res 10 2004 1409 1420
73. Chu I, Blackwell K, Chen S, and Slingerland J The dual ErbB1/ErbB2 inhibitor lapatinib (GW572016) cooperates with tamoxifen to inhibit both cell proliferation and estrogen-dependent gene expression in antiestrogen resistant breast cancer Cancer Res 65 2005 18 25
74. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, and Angibaud P Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro Cancer Res 61 2001 131 137
75. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, and Detre S Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer Clin Cancer Res 7 2001 3544 3550
76. Johnston SRD, Head J, Valenti M, Detre S, and Dowsett M Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo Breast Cancer Res Treat 76 2002 A245
77. Ellis CA, Vos MD, Wickline M, Riley C, Vallecorsa T, Telford WG, Zujewskil J, and Clark GJ Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines Breast Cancer Res Treat 78 2003 59 67
78. Long BJ, Liu G, Marrinan CH, Black S, Gheyas F, and Nomeir A Combining the farnesyl transferase inhibitor (FTI) lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts Proc Am Assoc Cancer Res 45 2004 A3868
79. Doisneau-Sixou SF, Cestac P, Faye JC, Favre G, and Sutherland RL Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression Int J Cancer 106 2003 789 798
80. Rudolf J, Boulay A, Zumstein-Mecker S, Evans DB, O' Reilly T, and Lane HA The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative FAD001 with the aromatase inhibitor letrozole in breast carcinomas Proc Am Assoc Cancer Res 45 2004 A5619
81. DeGraffenried LA, Friedrichs WE, Russel DH, Donzis EJ, and Middleton AK Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity Clin Cancer Res 10 2004 8059 8067
82. Johnston SRD Combinations of endocrine and biological therapies; present status of therapeutic and pre-surgical studies Clin Cancer Res 11 2005 889s 899s